Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (1157)	9/14/1998 10:19:00 PM
From: Ed Ajootian	Respond to of 10280

David, A great series of posts -- thanks for the effort. Hadn't heard they had even started a Phase III study on r-floextine (for migraines), never mind being a month away from filing the NDA. Can you say where you saw or heard this info? Not sure this would have any effect on trying to get into bed with Lily on using the other isomer of this drug for a totally different indication. Wondering why it is taking so long to work out the labeling details with the FDA on Xopenex. I know the company has been gearing us up for this (saying "late '98" product launch), but we're now at 2.5 months and counting, from the day they got the Approvable Letter. It would seem to be short-term bearish given that the stock actually traded down on what was apparently very favorable piece in such a major newspaper as the NY Times. Still holding some October 45 calls & getting itchier by the minute .